Our study into CAMK2B as a potential therapeutic target for glioma has revealed that therapeutic strategies involving RNA-based therapies, chemical inhibitory compounds, and indirect targeting using MAPK kinase inhibitors possess distinct benefits and limitations. This evidence concerns the gene CAMK2B and glioma.